Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 70 | 9,163 | 30% |
| 2020 | 67 | 8,003 | 33% |
| 2021 | 54 |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 59% of the cases CMS names in Illinois; 24 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 97 | 8,273−2.9%/yr | −2.9%/yr | 5.82.0× | 94% | 9,750 in 2030+2.8%/yr |
| Dialysis access |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Michigan
| 2024 |
| 6,194 |
| 47% |
| 2025 est. | ≈ 6,130 | – |
| 2026 est. | ≈ 6,210 | – |
| 7,433 |
| 37% |
| 2022 | 53 | 7,111 | 42% |
| 2023 | 50 | 7,071 | 45% |
| 2024 | 47 | 6,194 | 47% |
| 2025 from claims | – | 6,130 5,626–6,486 | 48% |
| 2026 forecast | – | 6,211 5,465–7,168 | 48% |
| 2027 forecast | – | 6,242 5,336–7,439 | 48% |
| 2028 forecast | – | 6,272 5,234–7,680 | 49% |
| 2029 forecast | – | 6,302 5,147–7,903 | 50% |
| 2030 forecast | – | 6,331 5,072–8,113 | 50% |
In 2025, 26% inpatient hospital, 34% hospital outpatient, 6% surgery center, 34% office. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 3,751−11%/yr |
| −11%/yr |
| 3.2 |
| 4% |
| 3,700 in 2030−0.2%/yr |
| Indiana | 18 | 2,941−9.6%/yr | −9.6%/yr | 4.0 | 16% | 2,980 in 2030+0.2%/yr |
| Missouri | 19 | 2,750−14%/yr | −14%/yr | 4.2 | 21% | 3,390 in 2030+3.5%/yr |
| Kansas | 13 | 2,258−6.3%/yr | −6.3%/yr | 5.4 | 53% | 2,010 in 2030−1.9%/yr |
| Wisconsin | 15 | 1,979−9.4%/yr | −9.4%/yr | 3.3 | 2% | 2,150 in 2030+1.4%/yr |
| Minnesota | 9 | 1,536−8.4%/yr | −8.4%/yr | 3.2 | 0% | 2,960 in 2030+12%/yr |
| South Dakota | 13 | 1,501−0.4%/yr | −0.4%/yr | 11.2 | 76% | 1,800 in 2030+3%/yr |
| Nebraska | 9 | 1,170−1.7%/yr | −1.7%/yr | 4.4 | 62% | 2,150 in 2030+11%/yr |
| Iowa | 8 | 1,121−12%/yr | −12%/yr | 2.4 | 11% | 1,490 in 2030+4.9%/yr |
| North Dakota | 5 | 361−11%/yr | −11%/yr | 3.5 | 0% | 220 in 2030−8.1%/yr |
| 87 |
| 7,931−11%/yr |
| −11%/yr |
| 5.91.4× |
| 73% |
| 7,380 in 2030−1.2%/yr |
| Thrombectomy, IVC filters & venous stents | 28 | 2,235+1.2%/yr | +1.2%/yr | 1.61.2× | 18% | 3,030 in 2030+5.2%/yr |
| Carotid revascularization | 31 | 1,439−3.9%/yr | −3.9%/yr | 1.00.9× | 0% | 1,600 in 2030+1.8%/yr |
| Aortic endografts (EVAR/TEVAR) | 7 | 563−7.4%/yr | −7.4%/yr | 0.40.8× | 0% | 600 in 2030+1.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Medtronic leads with 53% of company spending on these surgeons in 2025, +29 pts on 2024.
In 2025, 12 companies reported engagement with Illinois’s surgeons worth $105K in consulting, speaking, meals and travel tied to these products, about $2,231 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.